[HTML][HTML] 肺癌免疫检查点抑制剂的联合治疗研究进展
郭寒菲， 白日兰， 崔久嵬 - Chinese Journal of Lung Cancer, 2020 - ncbi.nlm.nih.gov
检查点抑制剂（ immune checkpoint inhibitors, ICIs） 治疗是目前最常用的免疫治疗方案，
已被批准用于黑色素瘤、 肾癌、 头颈癌、 膀胱癌等多种肿瘤的临床治疗， 在肺癌治疗中更是取得 …
已被批准用于黑色素瘤、 肾癌、 头颈癌、 膀胱癌等多种肿瘤的临床治疗， 在肺癌治疗中更是取得 …
Advances in combination therapy of immune checkpoint inhibitors for lung cancer
GUO Hanfei, BAI Rilan, CUI Jiuwei - Zhongguo Fei Ai Za Zhi, 2020 - search.proquest.com
检查点抑制剂 (immune checkpoint inhibitors, ICIs) 治疗是目前最常用的免疫治疗方案,
已被批准用于黑色素瘤, 肾癌, 头颈癌, 膀胱癌等多种肿瘤的临床治疗, 在肺癌治疗中更是取得 …
已被批准用于黑色素瘤, 肾癌, 头颈癌, 膀胱癌等多种肿瘤的临床治疗, 在肺癌治疗中更是取得 …
[HTML][HTML] 可切除非小细胞肺癌新辅助免疫治疗研究进展
QI Chang, T Panwen, LI Weimin - Chinese Journal of Lung Cancer, 2024 - ncbi.nlm.nih.gov
近年来， 免疫检查点抑制剂（ immune checkpoint inhibitors, ICIs） 对晚期非小细胞肺癌（ non-
small cell lung cancer, NSCLC） 患者预后的改善已成为共识， 越来越多的临床研究也逐渐证明 …
small cell lung cancer, NSCLC） 患者预后的改善已成为共识， 越来越多的临床研究也逐渐证明 …
免疫检查点抑制剂在小细胞肺癌治疗中的临床研究进展
黄本林， 段勇 - 中国肺癌杂志, 2019 - cqvip.com
随着人们对肿瘤免疫的深入研究, 以免疫检查点抑制剂(immune checkpoint inhibitor, ICI)
为重要代表的肿瘤免疫疗法在实体肿瘤方面取得了重大突破. 小细胞肺癌(small cell lung …
为重要代表的肿瘤免疫疗法在实体肿瘤方面取得了重大突破. 小细胞肺癌(small cell lung …
免疫检查点抑制剂治疗肺癌的临床研究进展
马荣， 宋婷婷， 冯婧劼 - 中国新药杂志, 2014 - cqvip.com
美国《 科学》 杂志将癌症免疫治疗列为2013 年最重大的科学突破. 在癌症免疫治疗中,
抑制免疫检查点通路被认为是最有前景的治疗方式之一. 过去的几年中, 已经有多个抑制免疫 …
抑制免疫检查点通路被认为是最有前景的治疗方式之一. 过去的几年中, 已经有多个抑制免疫 …
Combination of immune checkpoint inhibitors with chemotherapy in lung cancer
W Liu, L Zhang, Z Xiu, J Guo, L Wang… - OncoTargets and …, 2020 - Taylor & Francis
Tremendous progress has been achieved in the field of immune checkpoint inhibitors (ICIs)
therapy in lung cancer in recent years. To generate robust, long-lasting anti-tumor immune …
therapy in lung cancer in recent years. To generate robust, long-lasting anti-tumor immune …
[HTML][HTML] Current status of immune checkpoint inhibitor immunotherapy for lung cancer
W Xiong, Y Zhao, H Du, X Guo - Frontiers in oncology, 2021 - frontiersin.org
Immunotherapy is a major breakthrough in the treatment of cancer in recent years. Immune
checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed …
checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed …
非小细胞肺癌治疗新时代: 免疫治疗
Y Dong-mei, S Yong - Jie Fang Jun Yi Xue Za Zhi, 2017 - search.proquest.com
Immune checkpoint inhibitors have become an important alternative for advanced non-small
cell lung cancer (NSCLC) patients to surgery, chemotherapy, radiotherapy and targeted …
cell lung cancer (NSCLC) patients to surgery, chemotherapy, radiotherapy and targeted …
[HTML][HTML] Tumor immunology and immune checkpoint inhibitors in non-small cell lung cancer
CY Jung, SJ Antonia - Tuberculosis and respiratory diseases, 2018 - ncbi.nlm.nih.gov
Lung cancer is one of the most commonly diagnosed cancers and the leading cause of
cancer-related deaths worldwide. Although progress in the treatment of advanced non-small …
cancer-related deaths worldwide. Although progress in the treatment of advanced non-small …
Immune checkpoint inhibitors in the management of lung cancer
S Zimmermann, S Peters, T Owinokoko… - American Society of …, 2018 - ascopubs.org
Immune checkpoint inhibitors, specifically PD-1–directed agents, have changed the
treatment paradigm of non–small cell lung cancer (NSCLC) and are being actively …
treatment paradigm of non–small cell lung cancer (NSCLC) and are being actively …